Mechanism of Action
NPFF Receptor Activation
NPAF activates both NPFFR1 and NPFFR2, which are Gi/Go-coupled GPCRs. These receptors are expressed throughout pain-modulating circuits including the spinal cord dorsal horn, periaqueductal gray, and rostral ventromedial medulla. NPAF activation opposes opioid receptor signaling at multiple levels, reducing cAMP responses, counteracting opioid-induced receptor desensitization, and increasing excitatory neurotransmitter release.
Anti-Opioid and Pro-Nociceptive Effects
NPAF and related NPFF peptides are among the best-characterized anti-opioid peptides. They reduce morphine analgesia, accelerate tolerance development, and may produce hyperalgesia (pain sensitization) at higher doses. These effects are mediated through NPFFR1/2 and are blocked by RF-amide antagonists. NPAF may contribute to the rebound hyperalgesia observed after opioid withdrawal.
Research Summary
Opioid Tolerance
PreclinicalCo-administration of NPAF with morphine accelerates analgesic tolerance development in rodents. Conversely, NPFFR antagonists slow tolerance development and extend morphine efficacy. These findings have driven interest in developing NPFF receptor antagonists as opioid adjuvants that could extend analgesic benefit and reduce tolerance in chronic pain management.
Spinal Pain Processing
PreclinicalIntrathecal NPAF produces hyperalgesia and facilitates nociceptive transmission in the spinal dorsal horn. NPAF neurons in the superficial dorsal horn receive input from primary afferents and modulate pain signal processing. Their activation under inflammatory conditions contributes to central sensitization.
Calculate your Neuropeptide AF dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Opioid tolerance acceleration | 10-100 nmol ICV | Before opioid dosing | Intracerebroventricular |
| Pain modulation | 1-10 nmol IT | Single | Intrathecal |
Research tool only. NPFF receptor antagonists are the therapeutic development direction.
Interactions
Safety Profile
NPAF is an endogenous CNS peptide. Central administration produces hyperalgesia and pain sensitization. No therapeutic use. NPFF receptor antagonists that block NPAF/NPFF effects are in preclinical development as opioid adjuvants with potential clinical applications for chronic pain.
References
- [1]Yang HY et al. (1985). Neuropeptide FF, a F-8-F-amide peptide, antagonizes morphine analgesia without changing morphine induction. Science, 228(4701), 891-893.
- [2]Mollereau C et al. (2002). Distribution of NPFF1 and NPFF2 receptors in the rat brain and spinal cord. Synapse, 45(3), 191-203.